Last $291.00 USD
Change Today +3.01 / 1.05%
Volume 12.6K
RHHVF On Other Exchanges
Symbol
Exchange
OTC US
OTC US
OTC US
Xetra
SIX Swiss Ex
Xetra
SIX Swiss Ex
Mexico
Frankfurt
As of 5:20 PM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

roche holding ag-genusschein (RHHVF) Snapshot

Open
$289.00
Previous Close
$287.99
Day High
$291.01
Day Low
$288.68
52 Week High
02/24/14 - $340.18
52 Week Low
12/17/13 - $263.01
Market Cap
248.0B
Average Volume 10 Days
2.2K
EPS TTM
--
Shares Outstanding
702.6M
EX-Date
03/6/14
P/E TM
--
Dividend
$8.40
Dividend Yield
3.05%
Current Stock Chart for ROCHE HOLDING AG-GENUSSCHEIN (RHHVF)

roche holding ag-genusschein (RHHVF) Details

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses in Switzerland, European Union, and internationally. It discovers, develops, and provides diagnostic and therapeutic products and services that enable patients and healthcare professionals in the detection, prevention, diagnosis, treatment, and treatment monitoring of diseases. The company provides pharmaceutical products for various therapeutic areas comprising oncology, virology, inflammation, metabolic disorders, and central nervous system. In addition, it offers a portfolio of diagnostics products, such as blood glucose meters for diabetes patients; point-of-care testing devices for use in doctors’ offices; high-throughput analyzers for hospitals and commercial diagnostic laboratories; and start-of-the-art instruments and reagents for life science research. The company has a collaboration agreement with Astrazeneca Plc to develop a plasma-based companion diagnostic test to support AZD9291, a drug candidate for treating non-small-cell lung cancer; and a collaboration agreement with AmorChem L.P. to discover novel small molecule disease-modifying therapy for the treatment of myotonic muscular dystrophy 1 or Steinert's disease. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.

85,080 Employees
Last Reported Date: 01/30/14
Founded in 1896

roche holding ag-genusschein (RHHVF) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: SFr.5.1M
Compensation as of Fiscal Year 2013.

roche holding ag-genusschein (RHHVF) Key Developments

Roche Holding AG Reports Group Sales Results for the Third Quarter and Nine Months Ended September 2014; Provides Earnings Guidance for the Full Year of 2014

Roche Holding AG reported group sales results for the third quarter and nine months ended September 2014. For the period, the company reported group sales of CHF 34,757 million against CHF 34,867 million a year ago. For the third quarter, Roche's sales increased 1.8% from the similar period a year ago. The company posted sales of CHF 11.78 billion for July to September, up from CHF 11.57 billion a year earlier. For the full year 2014, the company expects low- to mid-single digit growth in Group sales at constant exchange rates. Core Earnings per share is targeted to grow ahead of sales.

Roche Say No To Mega-Merger

Roche Holding AG (SWX:ROG) will not consider launching a "mega-merger" in the pharmaceutical sector and instead focus on targeted opportunities to grow, Chief Executive Severin Schwan said. "We are screening the market for very targeted opportunities where we can build our existing franchises be it in diagnostics or pharma or technologies or products. but we are not into mega-mergers, we have a very targeted approach." Shares of Roche rose 1.95%.

Heidelberg Pharma Extends Research Partnership with Roche

Wilex AG announced that its unit Heidelberg Pharma extended its licence agreement with Roche for the development of Roche`s antibodies. Under the deal, first signed in 2013, Heidelberg Pharma will receive payments for providing its technology and research services to Roche. Furthermore, the German company could receive up to EUR 52 million (USD 65.7 million) for successful clinical development, regulatory approval and royalties for an undisclosed tumour target, the rights for which will be granted to Roche. In the partnership, Heidelberg uses its antibody drug conjugate technology, aiming at identifying and developing new antibody targeted amanitin conjugates, while Roche has the opportunity to obtain license for the development and marketing of selected conjugates.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RHHVF:US $291.00 USD +3.01

RHHVF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $25.45 USD +0.42
Gilead Sciences Inc $106.67 USD +4.46
Johnson & Johnson $100.36 USD +1.16
Merck & Co Inc $55.13 USD +1.08
Novartis AG SFr.83.55 CHF +0.75
View Industry Companies
 

Industry Analysis

RHHVF

Industry Average

Valuation RHHVF Industry Range
Price/Earnings 20.3x
Price/Sales 4.4x
Price/Book 12.3x
Price/Cash Flow 16.5x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCHE HOLDING AG-GENUSSCHEIN, please visit www.roche.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.